Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Operating Expenses: 2019-2025

Historic Operating Expenses for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $45.6 million.

  • C4 Therapeutics' Operating Expenses rose 4.67% to $45.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $159.9 million, marking a year-over-year increase of 4.51%. This contributed to the annual value of $155.2 million for FY2024, which is 2.87% down from last year.
  • C4 Therapeutics' Operating Expenses amounted to $45.6 million in Q3 2025, which was up 30.54% from $35.0 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Operating Expenses peaked at $45.6 million during Q3 2025, and registered a low of $27.9 million during Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $40.0 million (2023), whereas its average is $39.3 million.
  • Per our database at Business Quant, C4 Therapeutics' Operating Expenses spiked by 55.38% in 2021 and then fell by 16.86% in 2024.
  • C4 Therapeutics' Operating Expenses (Quarterly) stood at $35.3 million in 2021, then grew by 16.45% to $41.1 million in 2022, then declined by 1.12% to $40.7 million in 2023, then increased by 5.40% to $42.9 million in 2024, then rose by 4.67% to $45.6 million in 2025.
  • Its last three reported values are $45.6 million in Q3 2025, $35.0 million for Q2 2025, and $36.4 million during Q1 2025.